Top

Published in:

Open Access 01-12-2024 | Breast Cancer | Review

Drug resistance in breast cancer is based on the mechanism of exocrine non-coding RNA

Authors: Simin Ye, Shiyu Chen, Xiaoyan Yang, Xiaoyong Lei

Published in: Discover Oncology | Issue 1/2024

Abstract

Breast cancer (BC) ranks first among female malignant tumors and involves hormonal changes and genetic as well as environmental risk factors. In recent years, with the improvement of medical treatment, a variety of therapeutic approaches for breast cancer have emerged and have strengthened to accommodate molecular diversity. However, the primary way to improve the effective treatment of breast cancer patients is to overcome treatment resistance. Recent studies have provided insights into the mechanisms of resistance to exosome effects in BC. Exosomes are membrane-bound vesicles secreted by both healthy and malignant cells that facilitate intercellular communication. Specifically, exosomes released by tumor cells transport their contents to recipient cells, altering their properties and promoting oncogenic components, ultimately resulting in drug resistance. As important coordinators, non-coding RNAs (ncRNAs) are involved in this process and are aberrantly expressed in various human cancers. Exosome-derived ncRNAs, including microRNAs (miRNAs), long-noncoding RNAs (lncRNAs), and circular RNAs (circRNAs), have emerged as crucial components in understanding drug resistance in breast cancer. This review provides insights into the mechanism of exosome-derived ncRNAs in breast cancer drug resistance, thereby suggesting new strategies for the treatment of BC.

Fahad UM. Breast cancer: current perspectives on the disease status. Adv Exp Med Biol. 2019;1152:51–64. https://doi.org/10.1007/978-3-030-20301-6_4.CrossRef

Wang Y, Wang Y, Qin Z, et al. The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer. Expert Opin Drug Metab Toxicol. 2021;17(3):291–306. https://doi.org/10.1080/17425255.2021.1887139.CrossRefPubMed

Famta P, Shah S, Khatri DK, et al. Enigmatic role of exosomes in breast cancer progression and therapy. Life Sci. 2022;289:120210. https://doi.org/10.1016/j.lfs.2021.120210.CrossRefPubMed

Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022;95(1130):20211033. https://doi.org/10.1259/bjr.20211033.CrossRefPubMed

Duan H, Liu Y, Gao Z, et al. Recent advances in drug delivery systems for targeting cancer stem cells. Acta Pharm Sin B. 2021;11(1):55–70. https://doi.org/10.1016/j.apsb.2020.09.016.CrossRefPubMed

Aleskandarany MA, Vandenberghe ME, Marchiò C, et al. Tumour heterogeneity of breast cancer: from morphology to personalised medicine. Pathobiology. 2018;85(1–2):23–34. https://doi.org/10.1159/000477851.CrossRefPubMed

Dong X, Bai X, Ni J, et al. Exosomes and breast cancer drug resistance. Cell Death Dis. 2020;11(11):987. https://doi.org/10.1038/s41419-020-03189-z.CrossRefPubMedPubMedCentral

Goh C, Wyse C, Ho M, et al. Exosomes in triple negative breast cancer: garbage disposals or Trojan horses? Cancer Lett. 2020;473:90–7. https://doi.org/10.1016/j.canlet.2019.12.046.CrossRefPubMed

Buratta S, Tancini B, Sagini K, et al. Lysosomal exocytosis, exosome release and secretory autophagy: the autophagic- and endo-lysosomal systems go extracellular. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21072576.CrossRefPubMedPubMedCentral

10.

Isola AL, Chen S. Exosomes: the messengers of health and disease. Curr Neuropharmacol. 2017;15(1):157–65. https://doi.org/10.2174/1570159x14666160825160421.CrossRefPubMedPubMedCentral

11.

Wang X, Zhang H, Yang H, et al. Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer. Mol Oncol. 2020;14(3):539–55. https://doi.org/10.1002/1878-0261.12629.CrossRefPubMedPubMedCentral

12.

Iraci N, Leonardi T, Gessler F, et al. Focus on extracellular vesicles: physiological role and signalling properties of extracellular membrane vesicles. Int J Mol Sci. 2016;17(2):171. https://doi.org/10.3390/ijms17020171.CrossRefPubMedPubMedCentral

13.

Yi Y, Wu M, Zeng H, et al. Tumor-derived exosomal non-coding RNAs: the emerging mechanisms and potential clinical applications in breast cancer. Front Oncol. 2021;11:738945. https://doi.org/10.3389/fonc.2021.738945.CrossRefPubMedPubMedCentral

14.

Abels ER, Breakefield XO. Introduction to extracellular vesicles: biogenesis, RNA cargo selection, content, release, and uptake. Cell Mol Neurobiol. 2016;36(3):301–12. https://doi.org/10.1007/s10571-016-0366-z.CrossRefPubMedPubMedCentral

15.

Kalluri R. The biology and function of exosomes in cancer. J Clin Investig. 2016;126(4):1208–15. https://doi.org/10.1172/jci81135.CrossRefPubMedPubMedCentral

16.

Melo S, Sugimoto H, O’connell J, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014;26(5):707–21. https://doi.org/10.1016/j.ccell.2014.09.005.CrossRefPubMedPubMedCentral

17.

Najminejad H, Kalantar SM, Abdollahpour-Alitappeh M, et al. Emerging roles of exosomal miRNAs in breast cancer drug resistance. IUBMB Life. 2019;71(11):1672–84. https://doi.org/10.1002/iub.2116.CrossRefPubMed

18.

Chen F, Wang N, Tan HY, et al. The functional roles of exosomes-derived long non-coding RNA in human cancer. Cancer Biol Ther. 2019;20(5):583–92. https://doi.org/10.1080/15384047.2018.1564562.CrossRefPubMedPubMedCentral

19.

Koual M, Tomkiewicz C, Cano-Sancho G, et al. Environmental chemicals, breast cancer progression and drug resistance. Environ Health. 2020;19(1):117. https://doi.org/10.1186/s12940-020-00670-2.CrossRefPubMedPubMedCentral

20.

Szczygieł M, Markiewicz M, Szafraniec MJ, et al. Systemic mobilization of breast cancer resistance protein in response to oncogenic stress. Cancers. 2022. https://doi.org/10.3390/cancers14020313.CrossRefPubMedPubMedCentral

21.

Raheem F, Karikalan SA, Batalini F, et al. Metastatic ER+ breast cancer: mechanisms of resistance and future therapeutic approaches. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms242216198.CrossRefPubMedPubMedCentral

22.

Hashemi M, Arani HZ, Orouei S, et al. EMT mechanism in breast cancer metastasis and drug resistance: revisiting molecular interactions and biological functions. Biomed Pharmacother. 2022;155:113774. https://doi.org/10.1016/j.biopha.2022.113774.CrossRefPubMed

23.

Butti R, Gunasekaran VP, Kumar TVS, et al. Breast cancer stem cells: biology and therapeutic implications. Int J Biochem Cell Biol. 2019;107:38–52. https://doi.org/10.1016/j.biocel.2018.12.001.CrossRefPubMed

24.

Chaudhary P, Gibbs LD, Maji S, et al. Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis. Breast Cancer Res. 2020;22(1):11. https://doi.org/10.1186/s13058-020-1251-8.CrossRefPubMedPubMedCentral

25.

Liu J, Ren L, Li S, et al. The biology, function, and applications of exosomes in cancer. Acta Pharm Sin B. 2021;11(9):2783–97. https://doi.org/10.1016/j.apsb.2021.01.001.CrossRefPubMedPubMedCentral

26.

Yang X, Xie X, Liu S, et al. Engineered exosomes as theranostic platforms for cancer treatment. ACS Biomater Sci Eng. 2023. https://doi.org/10.1021/acsbiomaterials.3c00745.CrossRefPubMedPubMedCentral

27.

Mashouri L, Yousefi H, Aref AR, et al. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer. 2019;18(1):75. https://doi.org/10.1186/s12943-019-0991-5.CrossRefPubMedPubMedCentral

28.

Zijlstra A, Di Vizio D. Size matters in nanoscale communication. Nat Cell Biol. 2018;20(3):228–30. https://doi.org/10.1038/s41556-018-0049-8.CrossRefPubMedPubMedCentral

29.

Akoto T, Saini S. Role of exosomes in prostate cancer metastasis. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22073528.CrossRefPubMedPubMedCentral

30.

Kalluri R, Lebleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020. https://doi.org/10.1126/science.aau6977.CrossRefPubMedPubMedCentral

31.

Castaño C, Novials A, Párrizas M. Exosomes and diabetes. Diabet/Metab Res Rev. 2019;35(3): e3107. https://doi.org/10.1002/dmrr.3107.CrossRef

32.

To KKW, Huang Z, Zhang H, et al. Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy. Drug Resist Updat. 2024;73:101058. https://doi.org/10.1016/j.drup.2024.101058.CrossRefPubMed

33.

Ciravolo V, Huber V, Ghedini GC, et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol. 2012;227(2):658–67. https://doi.org/10.1002/jcp.22773.CrossRefPubMed

34.

Shedden K, Xie XT, Chandaroy P, et al. Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res. 2003;63(15):4331–7.PubMed

35.

Mishra A, Srivastava A, Pateriya A, et al. Metabolic reprograming confers tamoxifen resistance in breast cancer. Chem Biol Interact. 2021;347:109602. https://doi.org/10.1016/j.cbi.2021.109602.CrossRefPubMed

36.

Bitton A, Zheng Y, Houston JP, et al. Investigating differences between tamoxifen resistant and sensitive breast cancer cells with flow cytometry. Cytometry A. 2021;99(2):164–9. https://doi.org/10.1002/cyto.a.24306.CrossRefPubMedPubMedCentral

37.

Xu E, Guan T, Hu M, et al. Establishment and transcriptome characterization of tamoxifen-resistant canine mammary gland tumor cells. Res Vet Sci. 2022;145:135–46. https://doi.org/10.1016/j.rvsc.2022.02.018.CrossRefPubMed

38.

Semina SE, Scherbakov AM, Vnukova AA, et al. Exosome-mediated transfer of cancer cell resistance to antiestrogen drugs. Molecules. 2018. https://doi.org/10.3390/molecules23040829.CrossRefPubMedPubMedCentral

39.

Zhao Y, Jin L, Zhang X. Exosomal miRNA-205 promotes breast cancer chemoresistance and tumorigenesis through E2F1. Aging. 2021;13(14):18498–514. https://doi.org/10.18632/aging.203298.CrossRefPubMedPubMedCentral

40.

Liu J, Zhu S, Tang W, et al. Exosomes from tamoxifen-resistant breast cancer cells transmit drug resistance partly by delivering miR-9-5p. Cancer Cell Int. 2021;21(1):55. https://doi.org/10.1186/s12935-020-01659-0.CrossRefPubMedPubMedCentral

41.

Wei Y, Lai X, Yu S, et al. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res Treat. 2014;147(2):423–31. https://doi.org/10.1007/s10549-014-3037-0.CrossRefPubMed

42.

Andreeva O, Sorokin D, Mikhaevich E, et al. Towards unravelling the role of ERα-targeting miRNAs in the exosome-mediated transferring of the hormone resistance. Molecules. 2021. https://doi.org/10.3390/molecules26216661.CrossRefPubMedPubMedCentral

43.

Khalili-Tanha G, Moghbeli M. Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells. Cell Mol Biol Lett. 2021;26(1):39. https://doi.org/10.1186/s11658-021-00282-9.CrossRefPubMedPubMedCentral

44.

Mao L, Li J, Chen W, et al. Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs. Tumour Biol. 2016;37(4):5247–56. https://doi.org/10.1007/s13277-015-4402-2.CrossRefPubMed

45.

Yu DD, Wu Y, Zhang XH, et al. Exosomes from adriamycin-resistant breast cancer cells transmit drug resistance partly by delivering miR-222. Tumour Biol. 2016;37(3):3227–35. https://doi.org/10.1007/s13277-015-4161-0.CrossRefPubMed

46.

Chen WX, Xu LY, Qian Q, et al. Analysis of miRNA signature differentially expressed in exosomes from adriamycin-resistant and parental human breast cancer cells. 2018. Biosci Rep. https://doi.org/10.1042/bsr20181090.

47.

Chen WX, Liu XM, Lv MM, et al. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PLoS ONE. 2014;9(4): e95240. https://doi.org/10.1371/journal.pone.0095240.CrossRefPubMedPubMedCentral

48.

Li Y, Liang Y, Sang Y, et al. MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1. Cell Death Dis. 2018;9(1):14. https://doi.org/10.1038/s41419-017-0030-7.CrossRefPubMedPubMedCentral

49.

Zhao S, Pan T, Deng J, et al. Exosomal transfer of miR-181b-5p confers senescence-mediated doxorubicin resistance via modulating BCLAF1 in breast cancer. Br J Cancer. 2023;128(4):665–77. https://doi.org/10.1038/s41416-022-02077-x.CrossRefPubMed

50.

Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22(2):101–26. https://doi.org/10.1038/s41573-022-00579-0.CrossRefPubMed

51.

Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33–48. https://doi.org/10.1038/s41571-019-0268-3.CrossRefPubMed

52.

Derakhshani A, Rezaei Z, Safarpour H, et al. Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. J Cell Physiol. 2020;235(4):3142–56. https://doi.org/10.1002/jcp.29216.CrossRefPubMed

53.

Han M, Hu J, Lu P, et al. Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer. Cell Death Dis. 2020;11(1):43. https://doi.org/10.1038/s41419-020-2250-5.CrossRefPubMedPubMedCentral

54.

Zhang Z, Zhang L, Yu G, et al. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer. Cancer Chemother Pharmacol. 2020;86(6):761–72. https://doi.org/10.1007/s00280-020-04168-z.CrossRefPubMed

55.

Smith ER, Wang JQ, Yang DH, et al. Paclitaxel resistance related to nuclear envelope structural sturdiness. Drug Resist Updat. 2022;65:100881. https://doi.org/10.1016/j.drup.2022.100881.CrossRefPubMed

56.

Dan VM, Raveendran RS, Baby S. Resistance to intervention: paclitaxel in breast cancer. Mini Rev Med Chem. 2021;21(10):1237–68. https://doi.org/10.2174/1389557520999201214234421.CrossRefPubMed

57.

Yang Q, Zhao S, Shi Z, et al. Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling. J Exp Clin Cancer Res CR. 2021;40(1):120. https://doi.org/10.1186/s13046-021-01901-1.CrossRefPubMed

58.

Mattiske S, Suetani RJ, Neilsen PM, et al. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol Biomarkers Prev. 2012;21(8):1236–43. https://doi.org/10.1158/1055-9965.Epi-12-0173.CrossRefPubMed

59.

Santos JC, Lima NDS, Sarian LO, et al. Exosome-mediated breast cancer chemoresistance via miR-155 transfer. Sci Rep. 2018;8(1):829. https://doi.org/10.1038/s41598-018-19339-5.CrossRefPubMedPubMedCentral

60.

Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 2019;88:102925. https://doi.org/10.1016/j.bioorg.2019.102925.CrossRefPubMed

61.

Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–78. https://doi.org/10.1016/j.ejphar.2014.07.025.CrossRefPubMedPubMedCentral

62.

Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–83. https://doi.org/10.1038/onc.2011.384.CrossRefPubMed

63.

Wang B, Zhang Y, Ye M, et al. Cisplatin-resistant MDA-MB-231 cell-derived exosomes increase the resistance of recipient cells in an exosomal miR-423-5p-dependent manner. Curr Drug Metab. 2019;20(10):804–14. https://doi.org/10.2174/1389200220666190819151946.CrossRefPubMed

64.

Tutar Y. miRNA and cancer; computational and experimental approaches. Curr Pharm Biotechnol. 2014;15(5):429. https://doi.org/10.2174/138920101505140828161335.CrossRefPubMed

65.

Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629–41. https://doi.org/10.1016/j.cell.2009.02.006.CrossRefPubMed

66.

Sun YW, Chen YF, Li J, et al. A novel long non-coding RNA ENST00000480739 suppresses tumour cell invasion by regulating OS-9 and HIF-1α in pancreatic ductal adenocarcinoma. Br J Cancer. 2014;111(11):2131–41. https://doi.org/10.1038/bjc.2014.520.CrossRefPubMedPubMedCentral

67.

Luo J, Xiong Y, Fu PF, et al. Exosomal long non-coding RNAs: biological properties and therapeutic potential in cancer treatment. J Zhejiang Univ Sci B. 2019;20(6):488–95. https://doi.org/10.1631/jzus.B1900039.CrossRefPubMedPubMedCentral

68.

Josipovic I, Pflüger B, Fork C, et al. Long noncoding RNA LISPR1 is required for S1P signaling and endothelial cell function. J Mol Cell Cardiol. 2018;116:57–68. https://doi.org/10.1016/j.yjmcc.2018.01.015.CrossRefPubMed

69.

Serghiou S, Kyriakopoulou A, Ioannidis JP. Long noncoding RNAs as novel predictors of survival in human cancer: a systematic review and meta-analysis. Mol Cancer. 2016;15(1):50. https://doi.org/10.1186/s12943-016-0535-1.CrossRefPubMedPubMedCentral

70.

Marchese FP, Raimondi I, Huarte M. The multidimensional mechanisms of long noncoding RNA function. Genome Biol. 2017;18(1):206. https://doi.org/10.1186/s13059-017-1348-2.CrossRefPubMedPubMedCentral

71.

Yousefi H, Maheronnaghsh M, Molaei F, et al. Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance. Oncogene. 2020;39(5):953–74. https://doi.org/10.1038/s41388-019-1040-y.CrossRefPubMed

72.

Xu CG, Yang MF, Ren YQ, et al. Exosomes mediated transfer of lncRNA UCA1 results in increased tamoxifen resistance in breast cancer cells. Eur Rev Med Pharmacol Sci. 2016;20(20):4362–8.PubMed

73.

Tang S, Zheng K, Tang Y, et al. Overexpression of serum exosomal HOTAIR is correlated with poor survival and poor response to chemotherapy in breast cancer patients. J Biosci. 2019. https://doi.org/10.1007/s12038-019-9861-y.CrossRefPubMed

74.

Wang X, Pei X, Guo G, et al. Exosome-mediated transfer of long noncoding RNA H19 induces doxorubicin resistance in breast cancer. J Cell Physiol. 2020;235(10):6896–904. https://doi.org/10.1002/jcp.29585.CrossRefPubMed

75.

Zheng Z, Chen M, Xing P, et al. Increased expression of exosomal AGAP2-AS1 (AGAP2 antisense RNA 1) in breast cancer cells inhibits trastuzumab-induced cell cytotoxicity. Med Sci Monit. 2019;25:2211–20. https://doi.org/10.12659/msm.915419.CrossRefPubMedPubMedCentral

76.

Liu C, Lu C, Yixi L, et al. Exosomal Linc00969 induces trastuzumab resistance in breast cancer by increasing HER-2 protein expression and mRNA stability by binding to HUR. Breast Cancer Res. 2023;25(1):124. https://doi.org/10.1186/s13058-023-01720-6.CrossRefPubMedPubMedCentral

77.

Li Y, Zheng Q, Bao C, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015;25(8):981–4. https://doi.org/10.1038/cr.2015.82.CrossRefPubMedPubMedCentral

78.

Wang X, Chen T, Li C, et al. CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR. J Hematol Oncol. 2022;15(1):122. https://doi.org/10.1186/s13045-022-01345-w.CrossRefPubMedPubMedCentral

79.

Wei X, Tao S, Mao H, et al. Exosomal lncRNA NEAT1 induces paclitaxel resistance in breast cancer cells and promotes cell migration by targeting miR-133b. Gene. 2023;860:147230. https://doi.org/10.1016/j.gene.2023.147230.CrossRefPubMed

80.

Hu K, Liu X, Li Y, et al. Exosomes mediated transfer of Circ_UBE2D2 enhances the resistance of breast cancer to tamoxifen by binding to MiR-200a-3p. Med Sci Monit. 2020;26: e922253. https://doi.org/10.12659/msm.922253.CrossRefPubMedPubMedCentral

81.

Wu X, Ren Y, Yao R, et al. Circular RNA circ-MMP11 contributes to lapatinib resistance of breast cancer cells by regulating the miR-153-3p/ANLN Axis. Front Oncol. 2021;11:639961. https://doi.org/10.3389/fonc.2021.639961.CrossRefPubMedPubMedCentral

82.

Xia W, Chen W, Ni C, et al. Chemotherapy-induced exosomal circBACH1 promotes breast cancer resistance and stemness via miR-217/G3BP2 signaling pathway. Breast Cancer Res. 2023;25(1):85. https://doi.org/10.1186/s13058-023-01672-x.CrossRefPubMedPubMedCentral

Title: Drug resistance in breast cancer is based on the mechanism of exocrine non-coding RNA
Authors: Simin Ye
Shiyu Chen
Xiaoyan Yang
Xiaoyong Lei
Publication date: 01-12-2024
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Tamoxifen
Trastuzumab
Published in: Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-024-00993-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Harnessing exosomes in theranostic applications: advancements and insights in gastrointestinal cancer research

The combined effect of MTHFR C677T and A1298C polymorphisms on the risk of digestive system cancer among a hypertensive population

Nomogram for predicting survival in T1–T2 stage patients with supraglottic squamous cell carcinoma

PLCD3 inhibits apoptosis and promotes proliferation, invasion and migration in gastric cancer

Repression of LSD1/KDM1A activity improves the response of liver cancer cells to the lenvatinib

GALNT2 targeted by miR-139-5p promotes proliferation of clear cell renal cell carcinoma via inhibition of LATS2 activation

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials